HIV Prevention Drug Lenacapavir to Cost $40/Year in Over 100 Countries

Groundbreaking HIV Prevention Drug Accessibility

• 💊 A twice-yearly injectable HIV prevention drug, Lenacapavir, will be available for approximately $40 a year starting in 2027.
• 🌍 Generic versions will be produced by Indian pharmaceutical companies through agreements with Gilead Sciences, the Gates Foundation, and Unitaid.
• 🎯 These cheaper versions will be accessible in over 100 countries, aiming to make six-monthly PrEP a viable option for millions.

Efficacy and Current Cost

• 📈 Lenacapavir has demonstrated a reduction in HIV transmission risk by over 99.9%.
• 💸 Currently marketed as Yesgo by Gilead Sciences, the drug costs around $28,000 per year in the United States, a price that has been a barrier to curbing the epidemic.

Impact on HIV Epidemic Control

• 🚀 Experts believe that making this drug more affordable could be a turning point in the fight against HIV.
• 📉 While global efforts have reduced new HIV infections by 40% since 2010, 1.3 million people still contracted HIV in 2024, highlighting the continued need for effective prevention.
• 🌟 The availability of affordable Lenacapavir is seen as a critical step towards potentially ending HIV.